Crinetics Pharmaceuticals Inc (CRNX)

$43.01

-1

(-2.27%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Crinetics Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.67M → 346.0K (in $), with an average decrease of 64.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 6 quarters, -40.39M → -60.09M (in $), with an average decrease of 8.4% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.7% return, outperforming this stock by 71.7%

Performance

  • $42.87
    $44.45
    $43.01
    downward going graph

    0.33%

    Downside

    Day's Volatility :3.56%

    Upside

    3.24%

    downward going graph
  • $15.76
    $49.58
    $43.01
    downward going graph

    63.36%

    Downside

    52 Weeks Volatility :68.21%

    Upside

    13.25%

    downward going graph

Returns

PeriodCrinetics Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
21.15%
-0.7%
0.0%
6 Months
54.43%
7.7%
0.0%
1 Year
154.2%
3.3%
-1.7%
3 Years
165.99%
13.9%
-20.7%

Highlights

Market Capitalization
3.4B
Book Value
$7.91
Earnings Per Share (EPS)
-3.69
Wall Street Target Price
57.92
Profit Margin
0.0%
Operating Margin TTM
-5547.17%
Return On Assets TTM
-28.18%
Return On Equity TTM
-50.16%
Revenue TTM
4.0M
Revenue Per Share TTM
0.07
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-125.5M
EBITDA
-221.5M
Diluted Eps TTM
-3.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.29
EPS Estimate Next Year
-3.54
EPS Estimate Current Quarter
-0.86
EPS Estimate Next Quarter
-0.87

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Crinetics Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 34.67%

Current $43.01
Target $57.92

Technicals Summary

Sell

Neutral

Buy

Crinetics Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
-4.8%
54.43%
154.2%
165.99%
78.1%
Moderna, Inc.
Moderna, Inc.
-2.96%
23.83%
-28.58%
-37.0%
331.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.23%
10.55%
10.52%
78.91%
167.64%
Novo Nordisk A/s
Novo Nordisk A/s
-6.56%
25.69%
48.76%
237.69%
410.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
7.86%
19.8%
79.52%
133.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
NA
NA
NA
-3.29
-0.5
-0.28
NA
7.91
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.8
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.3
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
Buy
$3.4B
78.1%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.1B
331.65%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
167.64%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
410.4%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.49%
28.42
36.68%

Institutional Holdings

  • BlackRock Inc

    6.86%
  • Driehaus Capital Management LLC

    6.47%
  • Point72 Asset Management, L.P.

    5.42%
  • FMR Inc

    5.19%
  • State Street Corporation

    4.57%
  • Vanguard Group Inc

    4.49%

Corporate Announcements

  • Crinetics Pharmaceuticals Inc Earnings

    Crinetics Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

Organization
Crinetics Pharmaceuticals Inc
Employees
290
CEO
Dr. R. Scott Struthers Ph.D.
Industry
Health Technology

FAQs